Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer

Sponsor
Fudan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03792932
Collaborator
(none)
306
11
2
47.9
27.8
0.6

Study Details

Study Description

Brief Summary

Open distal pancreatectomy (ODP) has been commonly employed for the treatment of a variety of cancers in body and tail of pancreas. Although many general surgical procedures have been increasingly performed laparoscopically or with laparoscopic assistance, until the current decade, laparoscopic pancreatic surgery had not been performed for its complicated anatomy. But laparoscopic distal pancreatectomy (LDP) has been widely accepted as a standard treatment for body and tail pancreatic cancer because there is no anastomosis in it, and LDP has gradually become the first choice for these cancers in clinical work. Although there are several studies about the comparison between LDP and ODP, most are retrospective and there is no agreement in surgical margin, lymph node numbers and prognosis to identify the oncological differences between the two surgical approaches. The investigators' pilot study showed that patients with body and tail pancreatic cancer underwent LDP had a better prognosis compared with the ones undergoing ODP, with no statistics differences in postoperative complications and mortality. This perspective RCT study is performed to confirm whether LDP would improve the prognosis for patients with body and tail pancreatic cancer compared with ODP.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic distal pancreatectomy
  • Procedure: Open distal pancreatectomy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
306 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multicenter Prospective RCT Study of Laparoscopic Versus Open Distal Pancreatectomy in Patients With Pancreatic Cancer at the Body and Tail
Actual Study Start Date :
Feb 2, 2019
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Laparoscopic distal pancreatectomy

Procedure: Laparoscopic distal pancreatectomy
Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).

Active Comparator: Open distal pancreatectomy

Procedure: Open distal pancreatectomy
Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).

Outcome Measures

Primary Outcome Measures

  1. Recurrence Free Survival [2 years]

    RFS

Secondary Outcome Measures

  1. Overall Survival [2 years]

    OS

  2. R0 resection rate [2 years]

    R0 resection rate

  3. Detected lymph node number [2 years]

    Detected lymph node number

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≥ 19 years and ≤ 80 years, no gender limitation

  2. Resectable body and tail pancreatic cancer (refer to NCCN 2018)

  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  4. Tumor locates at the body and tail of the pancreas without distant metastasis

  5. No celiac trunk and superior mesenteric artery invasion

  6. No operation contraindication, fit for laparoscopic surgery

  7. The expected survival after surgery ≥ 3 months

  8. Patients who are willing and able to comply with the study procedure

  9. Signed informed content obtained prior to treatment

Exclusion Criteria:
  1. Locally advanced unresectable body and tail pancreatic cancer

  2. Multi-organ and vascular resection needed

  3. Patients undergoing total pancreatectomy

  4. Benign tumor at the body and tail of the pancreas or pancreatic cancer at the head of the pancreas

  5. Distant metastasis or ascites detected by imaging

  6. Severe important organ function impairment (heart, liver, kidney)

  7. Patients who are with other primary malignancy or haematological disorders

  8. Pregnant or nursing women

  9. Patients who have received chemotherapy, radiotherapy and interventional therapy before the pancreatectomy

  10. Patients who have participated in other clinical trials for pancreatic cancer treatment within 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Hefei Anhui China
2 Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Hebei Medical University Shijiazhuang Hebei China
3 Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin Heilongjiang China
4 Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
5 Department of Hepato-Pancreato-Biliary Surgery, The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu China
6 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University. Shanghai, China Shanghai Shanghai China 200032
7 Shanghai Changzheng Hospital Shanghai Shanghai China
8 West China Hospital Chengdu Sichuan China 610041
9 Department of Gastroenterology and Pancreatic Surgery, Zhejiang Provincial People's Hospital Hanzhou Zhejiang China
10 Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University Harbin China
11 Department of Biliopancreatic Surgery, Huadong Hospital, Fudan University Shanghai China

Sponsors and Collaborators

  • Fudan University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Xian-Jun Yu, Chair of Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Fudan University
ClinicalTrials.gov Identifier:
NCT03792932
Other Study ID Numbers:
  • CSPAC-2
First Posted:
Jan 4, 2019
Last Update Posted:
Jun 22, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2022